Avantor, Inc. (AVTR) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $7.60: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: Elevated put/call ratio: 3.00; Below-average business quality; Negative price momentum.
Avantor is a global provider of mission-critical products and services to biopharma, healthcare, education/government, and advanced technologies customers through its VWR distribution channel and specialty manufacturing brands (J.T. Baker, Masterflex, NuSil). It serves 300,000+... Read more
Sell if holding. Engine safety override at $7.60: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: Elevated put/call ratio: 3.00; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.4/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, earnings proximity 72d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
Recent Developments — Avantor, Inc.
Material events (past 30 days)
- Apr 23, 2026 MEDIUM Item 5.02: EVP Benoit Gourdier transitioning to new role supporting segment integration, expected to depart by December 31, 2026. Ludovic Brellier appointed EVP Bioscience and Medtech Products and Chief Transformation Officer effective May 1, 2026.
Latest news
- RBC Capital Reinstates Sector Perform on Avantor, Announces $9 Price Target — benzinga May 15, 2026 neutral
- Citigroup Maintains Neutral on Avantor, Lowers Price Target to $9 — benzinga Apr 30, 2026 negative
- Evercore ISI Group Maintains In-Line on Avantor, Lowers Price Target to $8 — benzinga Apr 30, 2026 neutral
- Transcript: Avantor Q1 2026 Earnings Conference Call — benzinga Apr 29, 2026 neutral
- Earnings Scheduled For April 29, 2026 — benzinga Apr 29, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-02-25Item 5.02LOW8-K/A: Simon Dingemans appointed to Audit & Finance Committee effective February 19, 2026, amending prior 8-K announcing his election as director in December 2025.SEC filing →
- 2026-02-25Item 5.02LOW8-K/A: Sanjeev Mehra appointed to Compensation & Human Resources Committee and Audit & Finance Committee effective February 19, 2026, amending prior 8-K announcing his election as director in December 2025.SEC filing →
- 2026-04-01Item 5.02HIGHCFO R. Brent Jones resigned to join a company outside life sciences, with 90 days notice. Steven Eck (SVP and Chief Accounting Officer) designated interim CFO pending permanent search. No permanent successor named.SEC filing →
- 2026-04-23Item 5.02MEDIUMEVP Benoit Gourdier transitioning to new role supporting segment integration, expected to depart by December 31, 2026. Ludovic Brellier appointed EVP Bioscience and Medtech Products and Chief Transformation Officer effective May 1, 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Unprofitable operations — net margin -8.4%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $7.60: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: Elevated put/call ratio: 3.00; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $7.24. Score 5.4/10, moderate confidence.
Take-profit target: $8.58 (+12.9% upside). Prior stop was $7.24. Stop-loss: $7.24.
Quality below floor (3.1 < 4.0).
Avantor, Inc. trades at a P/E of N/A (forward 8.9). TrendMatrix value score: 8.3/10. Verdict: Sell.
24 analysts cover AVTR with a consensus score of 2.8/5. Average price target: $10.
What does Avantor, Inc. do?Avantor is a global provider of mission-critical products and services to biopharma, healthcare, education/government,...
Avantor is a global provider of mission-critical products and services to biopharma, healthcare, education/government, and advanced technologies customers through its VWR distribution channel and specialty manufacturing brands (J.T. Baker, Masterflex, NuSil). It serves 300,000+ customer locations in approximately 180 countries with approximately 13,500 employees. More than 85% of net sales are recurring in nature; no single customer exceeds 5% of net sales.